Answers are grounded in this paper and cite their sources.
Case series reveals effective treatment for bloodstream infections in critically ill patients, suggesting new therapeutic strategies.
Background: Carbapenem-resistant Acinetobacter baumannii (CRAB), as a critical-priority pathogen among extensively drug-resistant (XDR) bacteria, influences healthcare-associated infections in China. Sulbactam–durlobactam (SUL-DUR) is recommended as a first-line agent for managing CRAB infections by the 2024 Infectious Diseases Society of America (IDSA) guidelines, but the usage of SUL-DUR for CRAB bloodstream infections (BSIs) has never been described in China. Methods: The present study aims to report five critically ill ICU patients recently treated in our center with CRAB BSIs who were successfully treated with SUL-DUR. Relevant literature and current guidelines are being briefly reviewed to provide a novel and promising clinical paradigm for managing BSI caused by CRAB. Findings: Use of SUL-DUR marked a definitive turning point in all five patients’ clinical trajectories. Conclusions: Our real-world evidence confirms SUL-DUR’s efficacy as a first-line agent for confirmed CRAB BSI cases and the definitive salvage therapy agent, impels a re-evaluation of the current clinical therapeutic spectrum for CRAB infection.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: